Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,378,767
  • Shares Outstanding, K 52,925
  • Annual Sales, $ 1,106 M
  • Annual Income, $ 54,500 K
  • 60-Month Beta 1.42
  • Price/Sales 4.74
  • Price/Cash Flow 19.23
  • Price/Book 4.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 2.03
  • Number of Estimates 2
  • High Estimate 2.14
  • Low Estimate 1.91
  • Prior Year 1.21
  • Growth Rate Est. (year over year) +67.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.30 +4.45%
on 09/21/20
124.60 -18.43%
on 08/26/20
-21.96 (-17.77%)
since 08/25/20
3-Month
73.64 +38.01%
on 06/29/20
137.61 -26.15%
on 08/06/20
+25.53 (+33.55%)
since 06/25/20
52-Week
46.37 +119.17%
on 03/23/20
137.61 -26.15%
on 08/06/20
+50.68 (+99.47%)
since 09/25/19

Most Recent Stories

More News
Athersys Gets FDA's RMAT Designation for Cell Therapy in ARDS

The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.

QGEN : 51.92 (+1.47%)
EBS : 101.63 (+2.54%)
ATHX : 2.04 (+2.00%)
HZNP : 78.25 (+3.88%)
Pfizer Seeks Xalkori's Label Expansion, Gets Priority Review

Pfizer's (PFE) sNDA seeking label expansion of lung cancer drug, Xalkori, for a hematologic indication gets priority review from the FDA.

PFE : 36.05 (+0.81%)
NVS : 87.11 (+0.94%)
EBS : 101.63 (+2.54%)
HZNP : 78.25 (+3.88%)
9 Meters Biopharma (NMTR) in Focus: Stock Moves 5.8% Higher

9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

EBS : 101.63 (+2.54%)
NMTR : 0.7646 (+4.85%)
NuCana (NCNA) Surges: Stock Moves 6.3% Higher

NuCana (NCNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

EBS : 101.63 (+2.54%)
NCNA : 5.21 (+4.20%)
Blueprint Medicines Up on Positive Top-Line Data From SM Study

Blueprint Medicines (BPMC) reports positive top-line results from the EXPLORER and the PATHFINDER studies, which are evaluating Ayvakit for patients with advanced systemic mastocytosis. Shares up.

QGEN : 51.92 (+1.47%)
EBS : 101.63 (+2.54%)
HZNP : 78.25 (+3.88%)
BPMC : 88.00 (-0.27%)
Genocea to Initiate a Phase I/II Oncology Study on GEN-011

Genocea's (GNCA) investigational new drug application to initiate a clinical study to evaluate its neoantigen-specific cell therapy candidate, GEN-011 in cancer patients gets FDA clearance.

EBS : 101.63 (+2.54%)
HZNP : 78.25 (+3.88%)
RGEN : 144.30 (+3.12%)
GNCA : 2.29 (+8.02%)
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA

The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.

BMY : 59.49 (+2.13%)
EBS : 101.63 (+2.54%)
TECH : 241.74 (+4.10%)
BLUE : 57.04 (+2.46%)
Axsome Expedites Development Plan for Narcolepsy Candidate

Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.

PFE : 36.05 (+0.81%)
EBS : 101.63 (+2.54%)
HZNP : 78.25 (+3.88%)
AXSM : 77.02 (+1.44%)
Alexion's New Formulation of Ultomiris Gets CHMP Backing

Alexion (ALXN) gets a positive opinion from the CHMP recommending marketing authorization for a new 100 mg/mL intravenous advanced formulation of Ultomiris in the EU.

ALXN : 114.43 (+2.15%)
EBS : 101.63 (+2.54%)
ALIM : 5.05 (unch)
TECH : 241.74 (+4.10%)
Axovant (AXGT) Catches Eye: Stock Jumps 12%

Axovant (AXGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

EBS : 101.63 (+2.54%)
AXGT : 4.72 (+10.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade EBS with:

Business Summary

Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining...

See More

Key Turning Points

2nd Resistance Point 104.18
1st Resistance Point 102.91
Last Price 101.63
1st Support Level 99.34
2nd Support Level 97.04

See More

52-Week High 137.61
Fibonacci 61.8% 102.76
Last Price 101.63
Fibonacci 50% 91.99
Fibonacci 38.2% 81.22
52-Week Low 46.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar